Panacea Life Sciences Holdings, Inc. (PLSH)

Every figure this model derived for PLSH, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 65,322 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 117,147 CashAndCashEquivalentsAtCarryingValue 2024-03-31
current assets 4,642,958 AssetsCurrent 2024-03-31
current liabilities 20,391,818 LiabilitiesCurrent 2024-03-31
equity -9,622,528 StockholdersEquity 2024-03-31
interest expense 1,605,392 InterestExpense 2024-03-31
ocf -1,567,702 NetCashProvidedByUsedInOperatingActivities 2024-03-31
revenue 2,763,922 RevenueFromContractWithCustomerExcludingAssessedTax 2024-03-31
sbc 0 ShareBasedCompensation 2021-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up PLSH on one particular measure came for.

RatioValue
cash operating margin-131.68
current ratio0.23
current ratio reported0.23
deferred revenue growth-100.0
dilution pct11.89
fcf margin-59.08
growth cv1.78
interest cover-3.31
operating margin-192.25
owner earnings margin-59.08
revenue growth50.38
revenue growth per share34.4
rule of 40-141.87
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about PLSH's figures. Written by the derivation as it ran, not added afterwards.